Sandra E. Dross

Aug 26, 2024 | cell.com | Alexander Cohen |Jennifer R. Keeffe |Sandra E. Dross |Allison J Greaney

Highlights • Pan-sarbecovirus vaccine evaluated in pre-vaccinated monkeys and mice • Mosaic nanoparticles elicited broad antibody responses after COVID-19 vaccinations • Epitope and molecular fate mapping revealed cross-reactive recall responses • Original antigenic sin did not diminish immune responses to a mosaic vaccine Summary Immunization with mosaic-8b (nanoparticles presenting 8 SARS-like betacoronavirus [sarbecovirus] receptor-binding domains [RBDs]) elicits more broadly...

May 22, 2024 | biorxiv.org | Alexander Cohen |Jennifer R. Keeffe |Ariën Schiepers |Sandra E. Dross

AbstractImmunization with mosaic-8b [60-mer nanoparticles presenting 8 SARS-like betacoronavirus (sarbecovirus) receptor-binding domains (RBDs)] elicits more broadly cross-reactive antibodies than homotypic SARS-CoV-2 RBD-only nanoparticles and protects against sarbecoviruses.

Feb 9, 2024 | biorxiv.org | Alexander Cohen |Jennifer R. Keeffe |Ariën Schiepers |Sandra E. Dross

AbstractImmunization with mosaic-8b [60-mer nanoparticles presenting 8 SARS-like betacoronavirus (sarbecovirus) receptor-binding domains (RBDs)] elicits more broadly cross-reactive antibodies than homotypic SARS-CoV-2 RBD-only nanoparticles and protects against sarbecoviruses.